Myasthenia gravis and neuromyelitis optica spectrum disorder A multicenter study of 16 patients


Autoria(s): Leite, M. I.; Coutinho, E.; Lana-Peixoto, M.; Apostolos, S.; Waters, P.; Sato, D.; Melamud, L.; Marta, M.; Graham, A.; Spillane, J.; Villa, A. M.; Callegaro, D.; Santos, E.; Silva, A. Martins da; Jarius, S.; Howard, R.; Nakashima, I.; Giovannoni, G.; Buckley, C.; Hilton-Jones, D.; Vincent, A.; Palace, J.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

07/11/2013

07/11/2013

2012

Resumo

Objective: To describe 16 patients with a coincidence of 2 rare diseases: aquaporin-4 antibody (AQP4-Ab)-mediated neuromyelitis optica spectrum disorder (AQP4-NMOSD) and acetylcholine receptor antibody (AChR-Ab)-mediated myasthenia gravis (AChR-MG). Methods: The clinical details and antibody results of 16 patients with AChR-MG and AQP4-NMOSD were analyzed retrospectively. Results: All had early-onset AChR-MG, the majority with mild generalized disease, and a high proportion achieved remission. Fifteen were female; 11 were Caucasian. In 14/16, the MG preceded NMOSD (median interval: 16 years) and 11 of these had had a thymectomy although 1 only after NMOSD onset. In 4/5 patients tested, AQP4-Abs were detectable between 4 and 16 years prior to disease onset, including 2 patients with detectable AQP4-Abs prior to thymectomy. AChR-Abs decreased and the AQP4-Ab levels increased over time in concordance with the relevant disease. AChR-Abs were detectable at NMOSD onset in the one sample available from 1 of the 2 patients with NMOSD before MG. Conclusions: Although both conditions are rare, the association of MG and NMOSD occurs much more frequently than by chance and the MG appears to follow a benign course. AChR-Abs or AQP4-Abs may be present years before onset of the relevant disease and the antibody titers against AQP4 and AChR tend to change in opposite directions. Although most cases had MG prior to NMOSD onset, and had undergone thymectomy, NMOSD can occur first and in patients who have not had their thymus removed. Neurology (R) 2012;78:1601-1607

Ministry of Education, Culture, Sports, Science & Technology of Japan (MEXT)

Ichiro Kanehara Foundation

Merck-Serono UK

Myasthenia Gravis Association, UK

Novartis

Teva

Bayer Schering Pharma

Biogen Idec

Mitsubishi Chemical Medience Corporation

Ministry of Education, Science and Technology of Japan

Bayer-Schering Healthcare

GW Pharma

Merz

SanofiAventis

Medical Research Council of United Kingdom

Identificador

NEUROLOGY, PHILADELPHIA, v. 78, n. 20, pp. 1601-1607, MAY, 2012

0028-3878

http://www.producao.usp.br/handle/BDPI/43269

10.1212/WNL.0b013e31825644ff

http://dx.doi.org/10.1212/WNL.0b013e31825644ff

Idioma(s)

eng

Publicador

LIPPINCOTT WILLIAMS & WILKINS

PHILADELPHIA

Relação

NEUROLOGY

Direitos

closedAccess

Copyright LIPPINCOTT WILLIAMS & WILKINS

Palavras-Chave #THYMIC MYOID CELLS #MULTIPLE-SCLEROSIS #WATER CHANNEL #THYMECTOMY #DISEASE #IMMUNOGLOBULIN #AUTOIMMUNITY #PATHOGENESIS #ANTIBODIES #DIAGNOSIS #CLINICAL NEUROLOGY
Tipo

article

original article

publishedVersion